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Total syntheses of alkaloid cis-223B and xenovenine are reported in 3 and 4 steps respectively using a 
two-directional synthesis / triple reductive amination strategy, and their neurotoxic properties assessed. 
 Pyrrolizidine alkaloids (PAs) are widely present in nature. In 
plants they are produced as a defence mechanism against insect 
herbivores, where more than 650 PAs and PA N-oxides have 10 
been isolated from 6000 different species (REF). This class of 
alkaloids is also present in moths, ants and poisonous frogs. The 
occurrence in anuran skin was first reported in 1993 for a 
Bufonid (Melanophryniscus) toad.1 To date, 26 3,5-PAs including 
stereoisomers have been assigned to the class. These compounds 15 
display a broad range of biological activity, including glucosidase 
inhibition and anti-HIV potency, and can also play a necrotic and 
allergic role against living organisms, as they are used as 
chemical defence by batrachians.2 There are cases where the 
same alkaloids have been isolated in myrmicin ants, raising the 20 
hypothesis that the presence of some alkaloids in frogs could be 
caused by their dietary source in this case, illustrated by alkaloid 
cis-223H.1 
 In order to quickly access this class of molecules, we proposed 
a simple bio-inspired approach through a triple reductive 25 
amination. Starting from a triketone, we would form in one step 2 
rings and 3 carbon-nitrogen bonds (Scheme 1). We surmised that 
the folded structure of the bicyclic system would enable us to 
attain the required stereochemistry by thermodynamic control. 
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Scheme 1. Retrosynthetic analysis 35 
 
 Although there is no direct biomimetic proof of the supposed 
synthetic pathway for these pyrrolizidines, we infered a similar 
mechanism to the one observed for alkaloid biosynthesis in ants 
and ladybirds.3 It has been particularly well documented in the 40 
case of coccinelline and precoccinelline.4  
 To explore our bio-inspired triple reductive amination strategy, 
two natural product targets were selected: the symmetrical 
alkaloid cis 223B 1, and non-symmetric (±)-xenovenine 2 
(Scheme 2). We surmised that adaption of our previous methods 45 
in two-directional synthesis5 would be highly suited to the simple 
synthesis of the triketone precursors. 
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Figure 1. Structures of alkaloid cis-223B and xenovenine 60 
 
 Alkaloid cis 223B contains two stereogenic centres. Its central 
planar symmetry provides a meso configuration. 1 Was identified 
by GC-MS for the first time in 1989 in bufonid toads 
Melanophrynzscus stelzneri (Argentina) and the frog Oophaga 65 
pumilio (Panama) but never was isolated.1,6 The first and only 
synthesis of alkaloid cis 223B was reported by our group in 2009: 
the latter was obtained in 7 steps and 43% overall yield.7 A 
synthesis of the trans configuration was later reported by 
Toyooka.8 (±)-Xenovenine was isolated in 1980 from the venom 70 
of the ant species Solenopsis xenoveneum by Jones and co-
workers.9 Structurally, this molecule is formed of a pyrrolizidine 
core with a 3,5-unsymmetrical substitution. Various syntheses of 
2 have been published between 1986 and 2000.10 The biological 
properties of either compound have not been reported. 75 
Results and discussion 
 Using a two-directional approach, our initial synthesis started 
with the acetal protection of diethyl 4-oxopimelate 3 to the diester 
4 (Scheme 2). The latter was then converted to Weinreb diamide 
5. The dialkylation of 5 with butylmagnesium bromide and 80 
subsequent deprotection of the central ketone gave access to the 
key triketone intermediate 7a in 4 linear steps and 39% yield. The 
process was then later streamlined by simply allowing the 
deprotection to occur directly after the alkylation. A further 
development even allowed access to 7a directly from 4, enabling 85 
in one pot: diamide formation, dialkylation and acetal 
deprotection in 25% overall yield. 
N
H
N
H
alkaloid cis 223B
1
(±) xenovenine
2
N
R1 R2
H
O
O O
R2R1
reductive
amination
 2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
  
Scheme 2. Synthesis of cyclisation precursors 
 
 To convert the triketone precursors 7a and 7b to the 
corresponding alkaloid cis-223B and the bis C3-analogue 8, 5 
several reductive amination conditions were attempted (Table 1). 
Conditions were optimised for the precursor 7b, with the best 
result obtained with 2 equivalents of sodium cyanoborohydride 
and 1.6 equivalents of ammonium acetate in methanol at 23 °C 
for 14 hours, giving a modest 29% yield of pyrrolizidine 8. These 10 
same conditions gave an improved 40% yield of alkaloid cis-
223B when applied to the reaction of the longer chain triketone 
7a. This increase in yield is likely down to the reduced volatility 
of the pyrrolizidine 1 vs 8. 
 Scheme 3. Synthesis of xenovenine 15 
Having successfully demonstrated our two-directional approach 
for the synthesis of alkaloid cis-223B and chain-shortened 
analogue 8, we next turned our attention to the the possibility of 
accessing non-symmetrical pyrrolizidines. Using a sequential 
Grignard addition strategy to symmetric protected diamide 6, 20 
with addition of the longer chain first, followed by the methyl 
group, we were able to gain access to the non-symmetrical 
triketone 9. The best isolated yield obtained for 9 after 
optimisation was 27% (Scheme 3). Our optimised conditions for 
the triple reductive cyclisation was then successfully applied to 25 
triketone 9, which, upon reaction gave (±)-xenovenine 2 as a 
single diasteroisomer in 24% yield. Jones reported a related triple 
reductive amination in his report of the isolation of xenovenine,11 
which gave a mixture of diastereomers. We were therefore 
particularly pleased to find that our optimised procedure gave the 30 
product as a single diastereomer. 
Biological evaluation 
 PAs are known to be toxic to humans and other mammals12 as 
well as insects.13 Most studies have focussed on PAs isolated 
from plants, and information about animal derived PAs is limited. 35 
The main toxic activity of plant PAs appears to be hepatotoxicity, 
caused indirectly by pyrrole metabolites.11 Other alkaloids 
isolated from anurans are known to display neurotoxic activity by 
interacting directly with specific ion channels within the nervous 
system. One recognised target is the nicotinic acetylcholine 40 
receptor.14 Binding studies have shown that twelve of thirteen 
plant PAs tested do not bind competitively to neuronal-nAChR,15 
Table 1. Optimisation of triple reductive amination of triketones 
 
 
 
Entry Solvent Reagents/eq Temp/ 
Time 
Produc
t 
Yield 
(%) 
1 MeOH NaBH3CN 2.0 
NH4OAc 1.6 
KOH 0.2 
RT 
14h 
8 13% 
2 MeOH NaBH3CN 2.0 
NH4OAc 1.6 
RT 
14h 
8 traces 
3 MeOH NaBH3CN 2.0 
NH4Cl 1.6 
RT 
14h 
8 29% 
4 THF NaBH(OAc)3 
3.0 
NH4OAc 5.0 
Cat. acetic acid 
60 °C 
1h 
8 25% 
5 EtOH NH3/EtOH 5.0 
Ti(OEt)4 2.5 
NaBH4 1.5 
RT 
14h 
8 7% 
6 HCO2H H2NCHO 12.0 170 °C 
4h 
8 - 
7 MeOH NaBH3CN 2.0 
NH4OAc 1.6 
RT 
14h 
1 40% 
8 MeOH Et3SiH 2.0 
NH4OAc 1.6 
RT 
14h 
8 - 
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but a number of PAs isolated from anuran skin display high 
affinity for Torpedo muscle-type nAChR.16 Spiropyrrolizidines 
are non-competitive antagonists of nAChR which display 
selectivity for neuronal over muscle-type receptors.17  Here we 
show inhibition of acetylcholine induced nAChR currents by cis-5 
223B and (±)-xenovenine using patch-clamp of TE671 cells 
expressing human muscle-type nAChR.18 The results shown in 
Figure 1 demonstrates clear, concentration dependent inhibition 
of the steady state current by both cis-223B and (±)-xenovenine, 
with IC50 values of 120µM and 43.2µM respectively. Both 10 
compounds clearly inhibit the nicotinic acetylcholine response at 
high concentrations but the IC50 values generated are modest 
when compared with other alkaloids isolated from anuran skin. 
Spiropyrrolizidines are known to show selectivity for neuronal 
over muscle-type nAChR,16 and it is possible that this is also true 15 
of these compounds. Further investigation into the selectivity of 
these compounds for neuronal-nAChR and different sub-types 
thereof would reveal their potential as therapeutic leads for 
nAChR abberations such as slow channel myasthenic syndrome. 
Figure 1. Inhibition of ACh (10µM) induced currents in TE671 cells 20 
expressing human muscle-type nAChR by a) cis 223B and b) (±) 
xenovenine at Vh -75mV. Typical traces showing ACh elicited currents 
(left) and when co-applied with pyrollizidines (100µM)(centre). Vertical 
bars represent 200pA and horizontal bars show 1s perfusion period. 
Concentration/inhibition plots fitted with non-linear regression curves. 25 
The current at 1s after onset (the point at which antagonism is greatest) 
was normalised against the preceding ACh only response at the same time 
point. Values represent mean ± SEM for 5-12 cells. 
Conclusions 
In conclusion we have applied a bio-inspired cascade reductive 30 
amination methodology to the synthesis of alkaloid cis-223B 1 (3 
steps, 10% yield) and C3-analogue 8 (3 steps, 8% yield).  This 
method was further developed to access unsymmetrical 
pyrrolizidine alkaloids, demonstrated by the diastereoselective 
synthesis of (±)-xenovenine 2 in 4 steps and 5% overall yield. 35 
Despite the relatively modest overall yields (partially due to 
volatility of the products), these synthetic pathways remain by far 
the shortest syntheses described for 1 and 2, and demonstrate the 
overall effectiveness of the combined two-directional synthesis / 
tandem reaction strategy.19 The overall strategy should be 40 
applicable to a wide range of 3,5-disubstituted pyrrolizidines. 
Furthermore, electrophysiology assays performed on nAChR 
from human muscle cells enabled us to determine the IC50s of 
both natural products, confirming for the first time the suspected 
neurotoxic properties of these natural products. 45 
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